- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | H.C. Wainwright maintains Buy rating on Lexeo Therapeutics stock | 4 | Investing.com | ||
| 07.04. | Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy | 2 | FierceBiotech | ||
| 07.04. | Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials | 1 | Benzinga.com | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.04. | Lexeo Reports Positive Interim Data Across All Dose Cohorts Of LX2006 | 1 | RTTNews | ||
| 07.04. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.04. | Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study | 80 | GlobeNewswire (Europe) | Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants... ► Artikel lesen | |
| 26.03. | H.C. Wainwright maintains Buy on Lexeo stock, $23 target | 1 | Investing.com | ||
| 25.03. | Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? | 2 | Insider Monkey | ||
| 24.03. | Lexeo Therapeutics Stock Jumps 23% Despite Widened Q4 Net Loss | 2 | RTTNews | ||
| 24.03. | Lexeo Therapeutics GAAP EPS of -$0.78 beats by $0.03 | 1 | Seeking Alpha | ||
| 24.03. | Leerink cuts Lexeo Therapeutics price target to $18, maintains Outperform | 1 | Investing.com | ||
| 24.03. | Lexeo Therapeutics, Inc. Loss At -$25.92 Mln In Q4 | 3 | RTTNews | ||
| 24.03. | Lexeo Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 24.03. | Lexeo Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 24.03. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.01. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.24 | Lexeo Therapeutics appoints new CFO amid growth | 2 | Investing.com | ||
| 19.12.24 | Lexeo Therapeutics names Kyle Rasbach as CFO | 1 | Seeking Alpha | ||
| 19.12.24 | Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer | 125 | GlobeNewswire (Europe) | NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular... ► Artikel lesen | |
| 19.12.24 | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,618 | -0,06 % | Sangamo-Aktie schießt hoch: Deal mit Eli Lilly - die Details | Mit einem Plus von gut 20 Prozent gehört die Aktie der Biotech-Gesellschaft Sangamo Therapeutics am Freitag zu den wenigen Aktien an der Börse, die mit einem sehr deutlichen Kursaufschlag gehandelt... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,280 | -0,87 % | Amended: Protalix Annual Earnings Fall | JERUSALEM (dpa-AFX) - (Amended: Recasting the story to correct the period, revenue)Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, Monday reported a decline in earnings for... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 21,200 | 0,00 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces QTORIN Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology ... | Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and... ► Artikel lesen | |
| ENZO BIOCHEM | 0,298 | +5,67 % | OTC Markets Group Welcomes Enzo Biochem, Inc. to OTCQX | NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Enzo Biochem... ► Artikel lesen | |
| CHECKPOINT THERAPEUTICS | 3,530 | +2,02 % | Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates | WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial... ► Artikel lesen | |
| SUTRO BIOPHARMA | 0,470 | -4,39 % | SUTRO BIOPHARMA, INC. - 8-K, Current Report | ||
| QUANTERIX | 5,150 | 0,00 % | Quanterix Provides Update on Financial Performance | BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced selected preliminary... ► Artikel lesen | |
| BELITE BIO | 49,800 | -1,39 % | BELITE BIO, INC - 6-K, Report of foreign issuer |
LEXEO THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.
